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Introduction
============

Patients with non-valvular atrial fibrillation and risk factors for thromboembolism require anticoagulant treatment to reduce the risk of stroke.[@ref1] [@ref2] The major complication with anticoagulant treatment is the increased risk of bleeding,[@ref3] particularly gastrointestinal bleeding.[@ref4] [@ref5] [@ref6]

After patients have experienced gastrointestinal bleeding during antithrombotic treatment, their clinicians face the clinical dilemma of whether to restart treatment or not. Moreover, there are several treatment regimens for clinicians to choose from: single or combined treatment with a vitamin K antagonist, a non-vitamin K antagonist oral anticoagulant, aspirin (acetylsalicylic acid), and an adenosine diphosphate receptor antagonist (clopidogrel, prasugrel, or ticagrelor).[@ref2] [@ref7] [@ref8] It is important to clarify how clinicians should treat patients with atrial fibrillation after antithrombotic related gastrointestinal bleeding; however, data on this are scarce, and no randomised controlled trial has been performed to elucidate the clinical dilemma regarding risk of stroke versus risk of bleeding in these patients.[@ref5] [@ref9] [@ref10]

In a nationwide cohort study, we examined the risk of all cause mortality and admission to hospital or deaths due to thromboembolism, major bleeding, or recurrent gastrointestinal bleeding associated with restarting antithrombotic treatment after a gastrointestinal bleed in patients with atrial fibrillation.

Methods
=======

In Denmark, all residents receive a unique and permanent civil registration number at birth or immigration that allows linkage between nationwide registries at an individual level. We obtained data from the following three sources. Firstly, the Danish national patient registry, which holds information on all hospital admissions since 1978 and at discharge; each hospital admission is coded with one primary and, if appropriate, one or more secondary diagnoses, in accordance with the International Classification of Diseases, the eighth revision until 1994 and the 10th revision thereafter. In addition, the registry keeps information on all procedures and surgical operations since 1996 (the Nordic Medical Statistics Committees classification of surgical procedures).[@ref11] Secondly, the Danish national prescription registry, which records all claimed drug prescriptions from pharmacies in Denmark since 1995.[@ref12] Finally, the Danish civil registration system, which contains information about an individual's vital status and cause of death.[@ref13]

Study population
----------------

We included all patients with atrial fibrillation who experienced gastrointestinal bleeding while receiving single or combined antithrombotic treatment with a vitamin K antagonist, dabigatran, rivaroxaban, aspirin, clopidogrel, prasugrel, or ticagrelor. Patients were included on the day of discharge from a first time admission to hospital owing to gastrointestinal bleeding in the study period from 1 January 1996 to 31 December 2012. We referred to the day of admission as the inclusion event and the day of discharge as the inclusion day.

In registries, the positive predictive value of bleeding related hospital admission is between 89% and 99%[@ref14]; that is, among all patients with a diagnosis code of bleeding, 89% to 99% were actually admitted to hospital with bleeding. Moreover, the agreement with regard to specific bleeding site suggests that misclassification is rare.[@ref14]

To assemble a homogeneous study population with atrial fibrillation and treated with antithrombotics, we excluded patients aged less than 30 or more than 100, patients with valvular heart disease, patients with total hip or knee replacement surgery up to eight weeks before the inclusion event, and patients with deep vein thrombosis or pulmonary embolism up to six months before the inclusion event.

Antithrombotic treatment
------------------------

To assess the resumption of antithrombotic treatment after discharge from hospital for gastrointestinal bleeding, we defined a 90 days blanking period---that is, follow-up did not start until inclusion day plus 90 days. All patients who died or experienced a thromboembolic event, major bleeding, or recurrent gastrointestinal bleeding in the 90 days blanking period were excluded. We divided the remaining patients who survived without an event until baseline, into groups according to type of antithrombotic treatment regimen restarted in the blanking period. The restarted groups were single treatment with oral anticoagulation (vitamin K antagonist, dabigatran, or rivaroxaban), single treatment with an antiplatelet agent (aspirin or an adenosine diphosphate receptor antagonist (clopidogrel, prasugrel, or ticagrelor)), and dual or triple treatment with oral anticoagulation, aspirin, and an adenosine diphosphate receptor antagonist.

We chose a blanking period of 90 days since in Denmark the numbers of tablets in the largest packet size available for antithrombotics last for approximately three months. This was done to remove the uncertainty about whether patients initially after discharge used antithrombotic drugs from an old package purchased before the gastrointestinal bleed. We kept records on the day each prescription was dispensed, the package size, and dosage. By using this method, we calculated patients' time dependent antithrombotic use during follow-up, as done in previous studies.[@ref4] [@ref15] [@ref16]

Concomitant medical treatment and comorbidities
-----------------------------------------------

To identify concomitant medical treatment at the time of the inclusion event, we used prescriptions filled from 0 to 90 days before the admission for gastrointestinal bleeding. To identify concomitant medical treatment at baseline, we used prescriptions filled during the 90 days blanking period. We determined comorbidities and invasive and surgical procedures from diagnosis and procedure codes based on validated methods.[@ref17] [@ref18] [@ref19] [@ref20]

We assessed stroke and bleeding risks with risk stratification schemes according to CHADS~2~ (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischaemic attack (double weight)), CHA~2~DS~2~-VASc (CHADS~2~ with vascular disease, age 65 to 74, and female sex added and double weight of age ≥75 years), and HAS-BLED (hypertension, abnormal renal or liver function, stroke, previous bleeding, international normalised ratio (left out because data are unfilled), elderly (age \>65 years), and drug (antiplatelet agents, non-steroidal anti-inflammatory drugs) or alcohol misuse) scores as in previous studies.[@ref15] [@ref21] A low CHADS~2~ or CHA~2~DS~2~-VASc score indicated a low risk of stroke, and a low HAS-BLED score indicated a low risk of bleeding. The predicted risk of stroke or bleeding increases when the scores increase. Supplementary table 1 lists all Anatomical Therapeutic Chemical Classification System codes, diagnosis codes, and invasive procedure codes used in the study.

Outcomes and follow-up
----------------------

The outcomes of interest were all cause mortality or admission to hospital or death due to thromboembolism, major bleeding, or recurrent gastrointestinal bleeding. We defined thromboembolism by diagnosis codes for ischaemic stroke, transient ischaemic attack, or systemic thromboembolism. Validation of the ischaemic stroke diagnosis showed that among all patients listed with ischaemic stroke in the Danish national patient registry, 97% to 100% truly had ischaemic stroke---that is, the positive predictive value was 97% to 100%. The positive predictive value for transient ischaemic attack ranges from 57.9% to 68.4%.[@ref19] Major bleeding was determined by diagnosis codes of intracranial bleeding, or severe bleeding from the respiratory, gastrointestinal, or urinary tract.[@ref14] We identified recurrent gastrointestinal bleeding by all diagnosis codes of gastrointestinal bleeding.[@ref14]

Follow-up of patients was until either of the outcomes, death, five year follow-up, or 31 December 2012, whichever came first.

Statistical analysis
--------------------

We present the inclusion day and baseline characteristics as numbers and percentages or as means and standard deviations where appropriate. For categorical data we used χ^2^ tests.

To estimate the cumulative incidence of outcomes, taking into account the risk of death from other causes, we used the Aalen-Johansen method (competing risks).[@ref22]

We used time dependent Cox proportional hazards models to examine the risk of events during follow-up for the different groups restarting antithrombotic treatment, with patients not resuming antithrombotic treatment as reference. As the number of patients who restarted triple treatment was small, we excluded them from the analysis. We constituted the different antithrombotic treatment regimens as time varying covariates, which allowed patients to switch their treatment regimen during follow-up. The models were adjusted for factors in the CHA~2~DS~2~-VASc score and for treatment with antiplatelets during the 90 days blanking period. We considered a two sided significance level of less than 0.05 to be significant. We checked to ensure that the Cox models all fulfilled the proportional hazard assumption and linearity of continuous covariates (age). In addition, we explored relevant interactions without any clinical significant findings, including no sex based differences.

Data management and statistical analyses were performed using SAS (version 9.2 for Windows, SAS Institute, NC) and R (version 3.0.2 for Windows, R Foundation for Statistical Computing).

Patient involvement
-------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in the design and implementation of the study. There are no plans to involve patients in dissemination of the results.

Results
=======

Index study population
----------------------

Figure 1[](#fig1){ref-type="fig"} shows the selection of the study population from 1 January 1996 to 31 December 2012. Overall, 4602 patients with atrial fibrillation were discharged from hospital after a first time gastrointestinal bleed while receiving antithrombotic treatment, referred to as the inclusion day. Table 1[](#tbl1){ref-type="table"} presents the characteristics of these patients.

![**Fig 1** Selection of study population. Antiplatelets comprise aspirin or adenosine diphosphate receptor antagonists](stal027904.f1_default){#fig1}

###### 

 Characteristics of patients with inclusion bleeding event. Values are numbers (percentages) unless stated otherwise

  Characteristics                                                                    Total population (n=4602)
  ---------------------------------------------------------------------------------- ---------------------------
  Mean (SD) age, years                                                               78.3 (9.3)
  Women                                                                              2085 (45.3)
  Mean (SD) CHADS~2~ score                                                           2.1 (1.2)
  Mean (SD) CHA~2~DS~2~-VASc score                                                   3.6 (1.5)
  Mean (SD) HAS-BLED score                                                           2.6 (1.0)
  Antithrombotic treatment the day before the inclusion event:                       
   Single: oral anticoagulation                                                      1101 (23.9)
   Single: antiplatelets                                                             2450 (53.3)
   Dual: oral anticoagulation+antiplatelets                                          893 (19.4)
   Dual: aspirin+adenosine diphosphate receptor antagonists                          117 (2.5)
   Triple: oral anticoagulation+aspirin+adenosine diphosphate receptor antagonists   41 (0.9)
  Concomitant drugs:                                                                 
   Dipyridamole (persantin)                                                          199 (4.3)
   Heparin                                                                           20 (0.4)
   Non-steroidal anti-inflammatory drug                                              1126 (24.5)
   Proton pump inhibitor                                                             693 (15.1)
   H~2~ receptor antagonist                                                          121 (2.6)
  Comorbidities:                                                                     
   Stroke or thromboembolism                                                         1034 (22.5)
   Myocardial infarction                                                             681 (14.8)
   Ischaemic heart disease                                                           1749 (38.0)
   Peripheral arterial disease                                                       290 (6.3)
   Vascular disease                                                                  903 (19.6)
   Heart failure                                                                     1411 (30.7)
   Hypertension                                                                      2058 (44.7)
   Diabetes                                                                          743 (16.2)
   Chronic kidney disease                                                            304 (6.6)
   Liver failure                                                                     64 (1.4)
   Previous bleeding                                                                 635 (13.8)
   Alcohol misuse                                                                    219 (4.8)
   Gastroesophageal reflux                                                           45 (1.0)
   Gastric or duodenal ulcer                                                         302 (6.6)
   Gastritis                                                                         37 (0.8)
  Invasive and surgical procedures:                                                  
   Gastrointestinal surgery                                                          935 (20.3)
   Gastroscopy                                                                       1074 (23.3)

Outcomes after index bleeding event
-----------------------------------

Figure 2[](#fig2){ref-type="fig"} shows the cumulative incidences of outcomes after inclusion day accounting for competing risk of death. At two years the cumulative incidence of all cause mortality was 39.9% (95% confidence interval 38.4% to 41.3%, n=1745), thromboembolism 12.0% (11.0% to 13.0%, n=526), major bleeding 17.7% (16.5% to 18.8%, n=788), or recurrent gastrointestinal bleeding 12.1% (11.1% to 13.1%, n=546). The incidences of all cause mortality, major bleeding, and recurrent gastrointestinal bleeding increased noticeably within the first month after the inclusion day, whereas the incidence of thromboembolism showed a regular increase over two years.

![**Fig 2** Cumulative incidences of all cause mortality, thromboembolism, major bleeding, or recurrent gastrointestinal bleeding counted from day after discharge from hospital for antithrombotic related gastrointestinal bleeding. For outcomes thromboembolism, major bleeding, or recurrent gastrointestinal bleeding the model accounts for risk of death from other causes (competing risks)](stal027904.f2_default){#fig2}

Baseline study population
-------------------------

Overall, we excluded 1193 patients in the 90 days blanking period between the inclusion day and baseline (fig 1). The baseline study population thus comprised 3409 patients. Table 2[](#tbl2){ref-type="table"} shows the baseline characteristics of this population.

###### 

 Baseline characteristics of baseline study population. Values are numbers (percentages) unless stated otherwise

  Characteristics                                                                    Non-resumption   All antithrombotics   Single treatment   Dual treatment                
  ---------------------------------------------------------------------------------- ---------------- --------------------- ------------------ ---------------- ------------ -------------
  Patients                                                                           924 (27.1)       2485 (72.9)           725 (21.3)         1314 (38.5)      384 (11.3)   51 (1.5)
  Mean (SD) age (years)                                                              78.8 (9.5)       77.6 (9.2)            75.4 (9.2)         79.4 (9.0)       75.9 (8.8)   74.5 (10.9)
  Women                                                                              442 (47.8)       1079 (43.4)           282 (38.9)         672 (48.9)       128 (35.5)   18 (35.3)
  Mean (SD) CHADS~2~ score                                                           1.9 (1.2)        2.1 (1.2)             1.9 (1.2)          2.1 (1.2)        2.2 (1.2)    2.6 (1.4)
  Mean (SD) CHA~2~DS~2~-VASc score                                                   3.4 (1.5)        3.6 (1.5)             3.3 (1.6)          3.7 (1.5)        3.8 (1.4)    4.3 (2.0)
  Mean (SD) HAS-BLED score                                                           2.6 (0.9)        3.1 (1.0)             2.6 (0.9)          3.3 (1.0)        3.5 (1.0)    3.8 (1.0)
  Antithrombotic treatment on day before inclusion event:                                                                                                                    
  Single: oral anticoagulation                                                       219 (23.7)       627 (25.2)            511 (70.5)         62 (4.7)         51 (13.3)    2 (3.9)
   Single: antiplatelets                                                             589 (63.7)       1151 (46.3)           35 (4.8)           1049 (79.9)      47 (12.5)    20 (39.2)
   Dual: oral anticoagulation+antiplatelets                                          105 (11.4)       605 (24.4)            173 (23.9)         150 (11.4)       275 (71.6)   4 (7.8)
   Dual: aspirin+adenosine diphosphate receptor antagonists                          8 (0.9)          72 (2.9)              1 (0.1)            45 (3.4)         2 (0.5)      22 (43.2)
   Triple: oral anticoagulation+aspirin+adenosine diphosphate receptor antagonists   3 (0.3)          30 (1.2)              5 (0.7)            8 (0.6)          9 (2.3)      3 (5.9)
  Concomitant drugs:                                                                                                                                                         
   Dipyridamole (persantin)                                                          21 (2.3)         92 (3.7)              4 (0.6)            78 (5.9)         7 (1.8)      3 (5.9)
   Heparin                                                                           11 (1.2)         27 (1.1)              10 (1.4)           4 (0.3)          12 (3.1)     0
   Non-steroidal anti-inflammatory drugs                                             54 (5.8)         141 (5.7)             27 (3.7)           87 (6.6)         25 (6.5)     1 (2.0)
   Proton pump inhibitor                                                             836 (90.5)       2268 (91.3)           650 (90.0)         1201 (91.4)      357 (93.0)   49 (96.1)
   H~2~ receptor antagonist                                                          25 (2.7)         48 (1.9)              15 (2.1)           30 (2.5)         3 (0.8)      0
  Comorbidities:                                                                                                                                                             
   Stroke or thromboembolism                                                         163 (17.6)       586 (23.6)            154 (21.2)         316 (24.1)       94 (24.5)    19 (37.3)
   Myocardial infarction                                                             105 (11.4)       418 (16.8)            66 (9.1)           241 (18.3)       76 (19.8)    27 (52.9)
   Ischaemic heart disease                                                           334 (36.2)       1129 (45.4)           240 (33.1)         623 (47.4)       218 (56.8)   39 (76.5)
   Peripheral arterial disease                                                       59 (6.4)         172 (6.9)             34 (4.7)           99 (7.5)         34 (8.9)     2 (3.9)
   Vascular disease                                                                  150 (16.2)       542 (21.8)            92 (12.7)          315 (24.0)       99 (25.8)    28 (54.9)
   Heart failure                                                                     329 (35.6)       814 (32.8)            202 (27.9)         433 (33.0)       153 (39.8)   20 (39.2)
   Hypertension                                                                      289 (31.3)       1082 (43.5)           336 (46.3)         487 (37.1)       223 (58.1)   30 (58.8)
   Diabetes                                                                          119 (12.9)       401 (16.1)            119 (16.4)         199 (15.1)       68 (17.7)    13 (25.5)
   Chronic kidney disease                                                            71 (7.7)         184 (7.4)             46 (6.3)           106 (8.1)        29 (7.6)     2 (3.9)
   Liver failure                                                                     22 (2.4)         49 (2.0)              19 (2.6)           22 (1.7)         6 (1.6)      1 (2.0)
   Alcohol misuse                                                                    64 (6.9)         153 (6.2)             37 (5.1)           84 (6.4)         23 (6.0)     8 (15.7)
   Gastroesophageal reflux                                                           13 (1.4)         53 (2.1)              12 (1.7)           31 (2.4)         6 (1.6)      4 (7.8)
   Gastric or duodenal ulcer                                                         819 (88.6)       2127 (85.6)           631 (87.0)         1124 (85.5)      319 (83.1)   44 (86.3)
   Gastritis                                                                         102 (11.0)       388 (15.6)            101 (13.9)         213 (16.2)       64 (16.7)    8 (15.7)
  Invasive and surgical procedures:                                                                                                                                          
   Gastrointestinal surgery                                                          441 (47.7)       1220 (49.1)           381 (52.6)         614 (46.7)       193 (50.3)   23 (45.1)
   Gastroscopy                                                                       815 (88.2)       2237 (90.0)           660 (91.0)         1168 (88.9)      350 (91.2)   49 (96.1)

Triple treatment (n=11) not reported separately. For all categorical variables, P values \<0.05 were found except for non-steroidal anti-inflammatory drugs, proton pump inhibitors, H~2~ receptor antagonists, chronic kidney disease, liver failure, gastric or duodenal ulcer, gastrointestinal surgery, and gastroscopy.

The overall mean age of the baseline population was 77.9 (SD 9.3) years, and 44.6% (n=1521) of the patients were women. The mean CHA~2~DS~2~-VASc score was 3.6 (SD 1.5) and mean HAS-BLED score was 3.0 (SD 1.0).

Antithrombotic treatment was restarted in 72.9% (n=2485) of the patients: single treatment with oral anticoagulation (21.3%, n=725), aspirin (35.5%, n=1212), or an adenosine diphosphate receptor antagonist (3.0%, n=102); dual treatment with oral anticoagulation plus aspirin (10.7%, n=363), oral anticoagulation plus an adenosine diphosphate receptor antagonist (0.6%, n=21), or aspirin plus an adenosine diphosphate receptor antagonist (1.5%, n=51); or triple treatment with oral anticoagulation plus aspirin plus an adenosine diphosphate receptor antagonist (0.3%, n=11). Of 725 patients who restarted single treatment with oral anticoagulation, 10 patients restarted dabigatran and one rivaroxaban. Furthermore, 384 patients restarted dual treatment with oral anticoagulation plus an antiplatelet agent, of whom two received dabigatran plus an antiplatelet agent. Non-vitamin K antagonist oral anticoagulants were not included in the other baseline groups.

Cumulative incidences
---------------------

Figure 3[](#fig3){ref-type="fig"} shows cumulative incidences for all cause mortality, thromboembolism, major bleeding, or recurrent gastrointestinal bleeding stratified by baseline groups (similar to intention to treat) accounting for competing risk of death. The incidence of all cause mortality within the first five years increased significantly for non-resumption and restart of single treatment with antiplatelets compared with the other baseline groups. The cumulative incidence of thromboembolism was generally lowest for restart of oral anticoagulation; however, this was not significant in relation to the other baseline groups.

![**Fig 3** Cumulative incidences of all cause mortality, thromboembolism, major bleeding, or recurrent gastrointestinal bleeding after baseline, stratified by baseline groups. For outcomes thromboembolism, major bleeding, or recurrent gastrointestinal bleeding the model accounts for risk of death from other causes (competing risks). Antiplatelets comprise aspirin or adenosine diphosphate receptor antagonists](stal027904.f3_default){#fig3}

Risk of outcomes associated with antithrombotic treatment after baseline
------------------------------------------------------------------------

The median duration of follow-up was 2.0 years (interquartile range 0.7 to 4.0 years). Table 3[](#tbl3){ref-type="table"} presents the time dependent adjusted hazard ratios of outcomes with antithrombotic treatment during follow-up in patients surviving the first 90 days after gastrointestinal bleeding. The reference was non-resumption of antithrombotic treatment.

###### 

 Main results presenting hazard ratios (95% confidence intervals) for restarting antithrombotic treatment and associated risk of outcome

  Outcomes                              No of events   Single treatment      Dual treatment                              
  ------------------------------------- -------------- --------------------- --------------------- --------------------- ---------------------
  All cause mortality                   1730           0.39 (0.34 to 0.46)   0.76 (0.68 to 0.86)   0.41 (0.32 to 0.52)   0.88 (0.57 to 1.36)
  Thromboembolism                       496            0.41 (0.31 to 0.54)   0.76 (0.61 to 0.95)   0.54 (0.36 to 0.82)   0.79 (0.34 to 1.84)
  Major bleeding                        454            1.37 (1.06 to 1.77)   1.25 (0.96 to 1.62)   1.44 (1.00 to 2.08)   1.36 (0.54 to 3.43)
  Recurrent gastrointestinal bleeding   216            1.22 (0.84 to 1.77)   1.19 (0.82 to 1.74)   1.34 (0.79 to 2.28)   0.58 (0.08 to 4.30)

Restart of single treatment with oral anticoagulation was associated with the lowest rate of all cause mortality (hazard ratio 0.39, 0.34 to 0.46) and thromboembolism (0.41, 0.31 to 0.54). Among the different treatment regimens that were restarted, the risk of major bleeding was significantly increased only in patients who restarted single treatment with oral anticoagulation (1.37, 1.06 to 1.77); however, the risk of recurrent gastrointestinal bleeding associated with any of the restarted groups was not significantly different from the reference group.

Additional analyses stratifying the study population at the inclusion event into three groups according to CHA~2~DS~2~-VASc score \<2, CHA~2~DS~2~-VASc score 2 or 3, and CHA~2~DS~2~-VASc score \>3 indicated that a gradual increase of the CHA~2~DS~2~-VASc score at the inclusion event was associated with a gradual decrease in the risk of all cause mortality among patients who restarted single treatment with oral anticoagulation. Moreover, a HAS-BLED score \>3 at the inclusion event showed an increased associated risk of recurrent gastrointestinal bleeding in patients who restarted single treatment with oral anticoagulation (see supplementary table 3).

Based on the results from table 2, we performed a subgroup analysis stratifying patients into antithrombotic treatment at the inclusion event (single treatment with oral anticoagulation or an antiplatelet agent, or dual treatment with oral anticoagulation plus an antiplatelet agent). The results showed that independent of antithrombotic treatment before the gastrointestinal bleeding, restarting or modifying treatment to single treatment with oral anticoagulation was in general associated with the greatest effectiveness and a relative safety compared with other restarted treatment strategies and non-resumption of antithrombotic treatment (see supplementary table 4).

Concomitant proton pump inhibitor use after gastrointestinal bleeding
---------------------------------------------------------------------

We carried out a subgroup analysis including patients who received concomitant treatment with proton pump inhibitors after gastrointestinal bleeding (table 4[](#tbl4){ref-type="table"}).

###### 

 Subgroup analysis including patients with additional proton pump inhibitor use with hazard ratios (95% confidence intervals) for restart of antithrombotic treatment and associated risk of outcome

  Outcomes                              Single treatment      Dual treatment                              
  ------------------------------------- --------------------- --------------------- --------------------- ---------------------
  All cause mortality                   0.38 (0.32 to 0.45)   0.75 (0.67 to 0.85)   0.41 (0.31 to 0.53)   0.78 (0.49 to 1.24)
  Thromboembolism                       0.40 (0.30 to 0.54)   0.75 (0.60 to 0.95)   0.57 (0.37 to 0.87)   0.77 (0.33 to 1.80)
  Major bleeding                        1.45 (1.10 to 1.91)   1.26 (0.95 to 1.67)   1.50 (1.02 to 2.22)   1.44 (0.57 to 3.67)
  Recurrent gastrointestinal bleeding   1.26 (0.85 to 1.87)   1.09 (0.73 to 1.64)   1.30 (0.74 to 2.29)   0.58 (0.08 to 4.36)

Sensitivity analyses
--------------------

Supplementary table 2 presents the numbers and risks of events within one year of follow-up, and the results showed consistency with the main results in table 3. Supplementary figure 1 shows cumulative incidences of events within five years after the inclusion day.

For the purpose of sensitivity analyses, we changed the 90 days blanking period to 30, 60, and 120 days. The results based on a shorter or longer blanking period supported the main results with the 90 days blanking period (table 5[](#tbl5){ref-type="table"}).

###### 

 Sensitivity analyses with hazard ratios (95% confidence intervals) based on 30, 60, or 120 days blanking periods

  Blanking periods                                              Outcomes                                                          
  ------------------------------------------------------------- --------------------- --------------------- --------------------- ---------------------
  **30 days blanking period\***                                                                                                   
  No of events                                                  2063                  581                   570                   294
  Single treatment:                                                                                                               
   Oral anticoagulation (n=783)                                 0.39 (0.34 to 0.45)   0.45 (0.35 to 0.59)   1.31 (1.02 to 1.68)   1.22 (0.86 to 1.72)
   Antiplatelets (n=1814)                                       0.79 (0.71 to 0.87)   0.80 (0.66 to 0.96)   1.24 (1.00 to 1.55)   1.21 (0.90 to 1.64)
  Dual treatment:                                                                                                                 
   Oral anticoagulation+antiplatelets (n=663)                   0.50 (0.41 to 0.61)   0.58 (0.41to 0.83)    1.28 (0.93 to 1.75)   1.13 (0.72 to 1.77)
   Aspirin+adenosine diphosphate receptor antagonists (n=115)   0.74 (0.50 to 1.09)   0.68 (0.32 to 1.48)   2.06 (1.13 to 3.74)   1.88 (0.79 to 4.51)
  **60 days blanking period†**                                                                                                    
  No of events                                                  1857                  532                   490                   234
  Single treatment:                                                                                                               
   Oral anticoagulation (n=707)                                 0.38 (0.33 to 0.45)   0.43 (0.33 to 0.57)   1.40 (1.08 to 1.82)   1.23 (0.84 to 1.78)
   Antiplatelets (n=1575)                                       0.79 (0.71 to 0.88)   0.79 (0.65 to 0.97)   1.30 (1.03 to 1.64)   1.28 (0.92 to 1.78)
  Dual treatment:                                                                                                                 
   Oral anticoagulation+antiplatelets (n=506)                   0.49 (0.40 to 0.61)   0.59 (0.40 to 0.86)   1.47 (1.05 to 2.06)   1.44 (0.89 to 2.33)
   Aspirin+adenosine diphosphate receptor antagonists (n=84)    0.81 (0.53 to 1.22)   0.85 (0.39 to 1.83)   1.52 (0.70 to 3.30)   0.50 (0.07 to 3.60)
  **120 days blanking period‡**                                                                                                   
  No of events                                                  1414                  408                   390                   177
  Single treatment:                                                                                                               
   Oral anticoagulation (n=724)                                 0.36 (0.30 to 0.43)   0.43 (0.31 to 0.58)   1.41 (1.05 to 1.88)   1.17 (0.76 to 1.79)
   Antiplatelets (n=1182)                                       0.77 (0.69 to 0.87)   0.77 (0.61 to 0.96)   1.37 (1.06 to 1.78)   1.25 (0.86 to 1.83)
  Dual treatment:                                                                                                                 
   Oral anticoagulation+antiplatelets (n=333)                   0.44 (0.34 to 0.58)   0.52 (0.33 to 0.81)   1.63 (1.12 to 2.37)   1.48 (0.86 to 2.55)
   Aspirin+adenosine diphosphate receptor antagonists (n=50)    0.76 (0.47 to 1.25)   0.99 (0.43 to 2.28)   1.52 (0.61 to 3.78)   0.66 (0.09 to 4.86)

\*Excluded 731 patients during blanking period. 437 patients did not resume treatment, 32 used triple treatment (oral anticoagulation+aspirin+adenosine diphosphate receptor antagonist.

†Excluded 1005 patients during blanking period. 704 patients did not resume treatment, 21 used triple treatment (oral anticoagulation+aspirin+adenosine diphosphate receptor antagonist.

‡Excluded 1338 patients during blanking period. 968 patients did not resume treatment, 7 used triple treatment (oral anticoagulation+aspirin+adenosine diphosphate receptor antagonist.

We carried out four additional sensitivity analyses. Firstly, we used unadjusted Cox models. Secondly, we adjusted the Cox models for potential confounders according to previous gastroscopy, cancer, chronic kidney disease, liver failure, alcohol misuse, and the use of non-steroidal anti-inflammatory drugs and dipyridamole 90 days before baseline. Thirdly, we carried out analyses with oral anticoagulation separated into vitamin K antagonists and non-vitamin K antagonist oral anticoagulants, and antiplatelets separated into aspirin and adenosine diphosphate receptor antagonists. Finally, we carried out analyses with follow-up starting the day after discharge (without the 90 days blanking period), assuming patients continued with the same antithrombotic treatment after discharge as before the inclusion event, and until they ran out of tablets. Supplementary table 5 shows the results of the sensitivity analyses; overall, the results were similar to the main results in table 3.

Discussion
==========

In this nationwide study of 4602 patients with non-valvular atrial fibrillation who were discharged from hospital after a gastrointestinal bleeding event while receiving antithrombotic treatment, we found the cumulative incidence of death was high; 39.9% within two years. Secondly, 27.1% of the patients did not resume antithrombotic treatment after the gastrointestinal bleed. Thirdly, among patients surviving the first 90 days after gastrointestinal bleeding, restarting single treatment with oral anticoagulation was associated with the lowest risk of all cause mortality and thromboembolism compared with non-resumption of antithrombotic treatment. Fourthly, none of the restarted antithrombotic treatment regimens was associated with a significantly increased risk of recurrent gastrointestinal bleeding.

Gastrointestinal bleeding as a powerful indicator of death
----------------------------------------------------------

Gastrointestinal bleeding is a serious event with high case fatality, and this study supports the results from the UK national audit 2007.[@ref23] Gastrointestinal bleeding is associated with a high mortality, especially among elderly patients with atrial fibrillation and multiple comorbidities who take antithrombotics, which is in accordance with our results and those of other studies.[@ref24] These findings reinforce the importance of gastrointestinal bleeding as a powerful indicator of death---that is, in our study 39.9% of patients died within two years after gastrointestinal bleeding. Stroke prevention among these high risk patients is a clinical challenge and a multidisciplinary task.

Antithrombotic treatment after gastrointestinal bleeding
--------------------------------------------------------

The decision not to resume antithrombotic treatment might be made to avoid rebleeding at the expense of an increased risk of stroke after gastrointestinal bleeding in patients with atrial fibrillation, and our observational data showed that 27.1% of patients did not resume antithrombotic treatment after gastrointestinal bleeding. In a comparable retrospective study, Qureshi and colleagues[@ref9] reported that 50.9% of patients with atrial fibrillation did not resume warfarin treatment after gastrointestinal bleeding. In the present study it was an option for patients to restart single treatment with antiplatelets, and we found that a large proportion started this treatment (aspirin 35.5% and adenosine diphosphate receptor antagonist 3.0%) with a mean CHA~2~DS~2~-VASc score of 3.7 (SD 1.5), despite that it has been established that patients with atrial fibrillation have the most net-clinical benefit from single treatment with oral anticoagulation.[@ref1] [@ref16] [@ref25] [@ref26] This is further supported by our study, which suggests that after gastrointestinal bleeding the benefits of restarting oral anticoagulation outweigh the risks of recurrent bleeding compared with other antithrombotic treatment regimens or non-resumption of antithrombotics---that is, single treatment with oral anticoagulation reduced mortality. Furthermore, this is in agreement with the study by Qureshi and colleagues, who reported benefit of restarting warfarin on mortality and thromboembolism and without the additional cost of recurrent gastrointestinal bleeding.[@ref9] Similarly, Witt and colleagues[@ref27] found that after gastrointestinal bleeding, restarting warfarin treatment compared with no treatment was associated with a lower risk of death and thromboembolism without a significantly increased risk of recurrent gastrointestinal bleeding. However, this study did not focus solely on patients with atrial fibrillation. A randomised controlled trial by Sung and colleagues[@ref28] tested continuation of single treatment with aspirin compared with no treatment after ulcer related bleeding. Despite the study's small sample size of 156 patients initially treated with aspirin as prophylaxis for cardiovascular or cerebrovascular diseases, the authors concluded that continuing aspirin treatment versus non-resumption potentially reduced mortality but increased the risk of recurrent gastrointestinal bleeding. The results of our observational study draw a parallel to those of that study, that restarting treatment is beneficial and outweighs the risks of recurrent bleeding; however, our study exclusively included patients with atrial fibrillation, and they benefited most from restarting single treatment with oral anticoagulation.

In the current study, patients who restarted single treatment with antiplatelets or combination treatment had the highest risk scores of stroke and bleeding, as indicated by the CHA~2~DS~2~-VASc score and HAS-BLED score, respectively. Even though we adjusted for these risk scores, confounding by indication may have influenced our results leading to an underestimation of subsequent stroke and an overestimation of recurrent bleeding in these treatment groups. However, this study came across a surprising finding---that patients who restarted single treatment with oral anticoagulation and those who did not resume antithrombotic treatment had similar risk scores for stroke (CHA~2~DS~2~-VASc: 3.3 (SD 1.6) and 3.4 (SD 1.5), respectively) and bleeding (HAS-BLED: 2.6 (SD 0.9) and 2.6 (SD 0.9), respectively), but during follow-up patients who restarted single treatment with oral anticoagulation benefited from a decreased associated risk of all cause mortality and thromboembolism without an increased risk of recurrent gastrointestinal bleeding. This suggests the need and importance of restarting single treatment with oral anticoagulation in patients with atrial fibrillation after gastrointestinal bleeding.

The blanking period
-------------------

During the 90 days blanking period, we missed a proportion of events. Moreover, the results could be less generalisable in a clinical every day practice, because the 90 days blanking period obscured what happened in terms of antithrombotic treatment within the first 90 days after the gastrointestinal bleeding. To evaluate the effect of changing the blanking period, we carried out sensitivity analyses not including the blanking period or changing the blanking period to 30, 60, or 120 days. The results from the sensitivity analyses supported the main results based on the 90 days blanking period.

Use of proton pump inhibitors after gastrointestinal bleeding
-------------------------------------------------------------

In international guidelines the use of proton pump inhibitors is indicated in patients with a history of gastrointestinal bleeding treated with dual antiplatelet drugs or concomitant anticoagulation treatment.[@ref29] [@ref30] In this study, the use of proton pump inhibitors after gastrointestinal bleeding in the groups who restarted antithrombotic treatment ranged from 90.0% to 96.1% at baseline, showing that recommendations are generally followed. The results from the subgroup analysis based on patients who restarted antithrombotic treatment and used concomitant proton pump inhibitors did not deviate much from the main results (table 4).

Restart of antithrombotic treatment and recurrent bleeding
----------------------------------------------------------

One of our objectives was to examine major bleeding, which to our knowledge has not been examined previously in the selected study population. In patients with atrial fibrillation, combination treatment is associated with a higher risk of major bleeding than is single treatment.[@ref4] Moreover, drug-drug interactions between antithrombotics increase the risk of gastrointestinal bleeding, and Delaney and colleagues[@ref31] concluded that dual treatment with aspirin added to warfarin or clopidogrel was associated with a greater risk of gastrointestinal bleeding than that observed with each drug alone. The present study found that single or dual treatment was not significantly associated with an increased risk of recurrent gastrointestinal bleeding; however, lack of statistical power could have influenced this result.

Non-vitamin K antagonist oral anticoagulants after gastrointestinal bleeding
----------------------------------------------------------------------------

In the past three or four years, the use of non-vitamin K antagonist oral anticoagulants is increasing at the expense of vitamin K antagonists,[@ref21] but owing to the paucity of data on non-vitamin K antagonist oral anticoagulants in the current study we cannot conclude anything on the efficacy or safety of these drugs in this setting. Consideration of the patient's profile is necessary when balancing the risks of stroke with recurrent bleeding after gastrointestinal bleeding in patients with atrial fibrillation.

Strengths and limitations of this study
---------------------------------------

The major strength of the present study was the opportunity to include a nationwide cohort of 4602 patients with atrial fibrillation independent of sex, age, socioeconomic status, or participation in health insurance programmes. All Danish residents are covered by a public health insurance system, which ensures registration of all hospital admissions and outpatient contacts. In addition, pharmacies register all claimed prescriptions, and the Danish registries are well validated.[@ref12] [@ref32] [@ref33] Aspirin, proton pump inhibitors, non-steroidal anti-inflammatory drugs, and H~2~ receptor antagonists are also available over the counter; however, owing to a partial reimbursement system in Denmark, chronic users mainly claim medicine on prescription. In 2012, 92% of all aspirin was sold as a prescription drug.[@ref34] The time dependent statistical models based on all prescriptions claimed added strength to the results, but from the registries we were not able to determine whether patients took their tablets after the prescription had been dispensed. This could have led to a potential overestimation of events in the groups who restarted antithrombotic drugs. Another limitation was that patients included near the end of the study had decreased risk time to develop an event. We used the major and non-major diagnosis codes of gastrointestinal bleeding to ensure high sensitivity, but no detailed clinical information was available for any of the events. We were not able to distinguish between lower and upper gastrointestinal bleeding, owing to lack of power.

The international normalised ratio levels, the quality of warfarin control, serum creatinine concentration, renal function, haemoglobin levels, and other potential confounders with no possibilities for identification in the registries, could have influenced our results. We attempted to minimise these influences by carrying out sensitivity analysis---for example, by adjusting for chronic kidney disease and by using methods from previous parallel studies.[@ref4] [@ref15] [@ref16]

The observational study design did not permit definite causations to be concluded; instead, we examined the associations between restart of antithrombotic treatment and outcomes. The demand for a randomised controlled trial on restarting oral anticoagulation and the risk of stroke and recurrent bleeding after a gastrointestinal bleeding among patients with atrial fibrillation is increasing, but such a trial would face many challenges.

Conclusion
----------

Mortality was high among patients with atrial fibrillation who were discharged from hospital after a gastrointestinal bleeding event while taking antithrombotics. More than a quarter did not resume treatment. However, among patients surviving the first 90 days after gastrointestinal bleeding, restarting single treatment with oral anticoagulation was associated with the lowest risk of all cause mortality and thromboembolism, and a relative safe use regarding the risk of recurrent bleeding, compared with non-resumption of antithrombotic treatment or restarting other antithrombotic treatment regimens.

### What is already known on this topic

1.  The gastrointestinal tract is the most common site of bleeding due to oral anticoagulant treatment among patients with atrial fibrillation

2.  Data on whether to restart antithrombotic treatment or withhold treatment after gastrointestinal bleeding are scarce

### What this study adds

1.  In this study over a third of patients with atrial fibrillation discharged after gastrointestinal bleeding while taking antithrombotics died within two years

2.  Under a third did not resume antithrombotics after gastrointestinal bleeding

3.  Restarting single treatment with oral anticoagulation was associated with the lowest risk of all cause mortality and thromboembolism, and a relative safe use regarding risk of recurrent bleeding, compared with non-resumption of antithrombotic treatment
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